fbpx
August 9, 2022

FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity

[8/9/2022] FDA recently became aware of a nitrosamine impurity, Nitroso-STG-19 (known as NTTP), in certain samples of sitagliptin, a medicine used to treat type 2 diabetes […]
August 9, 2022

Ariella Naturals – 632509 – 08/04/2022

Delivery Method: Via Email Product: Drugs Issuing Office: Center for Drug Evaluation and Research | CDER United States WARNING LETTER August 4, 2022 RE: 632509 To […]
August 9, 2022

JB Exchange Inc./Justified Laboratories – 631521 – 08/04/2022

Delivery Method: Via Email Product: Drugs Issuing Office: Center for Drug Evaluation and Research | CDER United States WARNING LETTER August 4, 2022 RE: 631521 Dear […]
August 9, 2022

Amazon.com, Inc. – 629452 – 08/04/2022

Delivery Method: Via Email Product: Drugs Issuing Office: Center for Drug Evaluation and Research | CDER United States WARNING LETTER August 4, 2022 RE: 629452 Dear […]
August 8, 2022

Rena’s Organic – 613036 – 02/11/2022

Delivery Method: Via Email Product: Dietary SupplementsDrugsFood & Beverages Recipient: Recipient Name Ms. Rena S. Greenberg Recipient Title Registered Agent Rena’s Organic 414 26th St WestBradenton, […]
August 5, 2022

Human Drug Compounding Outsourcing Facility Fees

Human Compounding Fee Payment Instructions When are fees incurred?Beginning in fiscal year (FY) 2015, outsourcing facilities that register with the FDA may incur one or more […]
August 5, 2022

American Health Packaging Issues Voluntary Nationwide Recall of Ranitidine Syrup (Ranitidine Oral Solution USP) 150 mg/10 mL Liquid Unit Dose Cups Due to the Detection of N-nitrosodimethylamine (NDMA) Impurity

Summary Company Announcement Date: November 08, 2019 FDA Publish Date: November 08, 2019 Product Type: Drugs Reason for Announcement: Recall Reason Description NDMA (Nitrosodimethylamine) impurity Company […]
August 5, 2022

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

For Immediate Release: August 05, 2022 Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable […]
August 5, 2022

FluxxLab LLC – 637158 – 08/04/2022

Product: Drugs Recipient: Recipient Name Arend John Kuijvenhoven FluxxLab LLC 1681 Niagara Rd.Montrose, CO 81401United States [email protected] WARNING LETTER RE: 637158 Date: August 4, 2022 TO: Arend […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0